Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis CEO resigns
The company has appointed Sigurdur Oli Olafsson, former deputy CEO of the company, as the new CEO. Mr Olafsson joined Actavis in 2003, after working for Pfizer UK
The company has appointed Sigurdur Oli Olafsson, former deputy CEO of the company, as the new CEO. Mr Olafsson joined Actavis in 2003, after working for Pfizer UK
As previously reported for Cohorts 1 and 2 of this study, R7128 has demonstrated potent short-term antiviral activity and was generally safe and well tolerated at doses of
The Medicines Company expects to start Phase I clinical testing of CU-2010 in 2008. This acquisition is said to give The Medicines Company an integrated development capability around
In May 2008, Pharmacopeia reduced its workforce by approximately 15% through attrition and termination of positions. With these two reductions, the company will have reduced its workforce in
The clinical trial is evaluating the safety and tolerability of both single and multiple doses of MTRX1011A. The initiation of the Phase I clinical trial resulted in the
AGS-004 achieved the trial’s primary endpoint of induction of T cell response to patient-specific HIV antigens. AGS-004 is a personalized HIV immunotherapy generated by the company’s Arcelis technology.
Vyteris’s pain management initiative will examine several candidate drugs to improve their safety and efficacy profiles using the company’s proprietary controlled drug delivery technology and to potentially extend
The Office of the Chief Scientist (OCS) has approved a special grant to support Modigene’s interferon-beta-CTP (IFN-Beta-CTP) program for 2008-2009. The grant will provide cash reimbursements of 40%
The patent-pending modular forceps and accessories are said to be designed to provide surgeons added comfort while reducing per-procedure costs through the reduction of inventory and obsolescence. According
TriMix gel has been prescribed by doctors as a first line and secondary treatment for erectile dysfunction (ED). American Pharmacy Solutions (APS) is a licensed compounding pharmacy which